Market Place
Sourcing Support
Qilu Pharma`s Generics Icosapent Ethyl Receives Approval in US
20 Nov 2024 //
FDA
REDUCE-IT Subanalysis on VASCEPA®/VAZKEPA® at AHA 2024
11 Nov 2024 //
GLOBENEWSWIRE
Research On VASCEPA To Be Presented At EASD Meeting
09 Sep 2024 //
GLOBENEWSWIRE
Amarin`s VAZKEPA Gets National Reimbursement In Portugal
17 Jul 2024 //
GLOBENEWSWIRE
Amarin`s Partner Gets China Approval For VASCEPA In Cardiovascular Risk
08 Jul 2024 //
GLOBENEWSWIRE
Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit
18 Jun 2024 //
REUTERS
Amarin: VAZKEPA Reimbursed In Greece, Deal With Vianex For Commercialization
28 May 2024 //
GLOBENEWSWIRE
New REDUCE-IT® Analyses Show VASCEPA Benefit in High-Risk Cardiovascular Disease
06 Apr 2024 //
GLOBENEWSWIRE
Amarin Provides Update on VAZKEPA® Intellectual Property Portfolio in Europe
03 Apr 2024 //
GLOBENEWSWIRE
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl)
25 Mar 2024 //
GLOBENEWSWIRE
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine
25 Mar 2024 //
GLOBENEWSWIRE
Strides launches Icosapent Ethyl Acid Soft Gel capsules in
02 Dec 2023 //
INDIAN PHARMA POST
Analyses Show VASCEPA Associated with 29% Reduction with Metabolic Syndrome
12 Nov 2023 //
GLOBENEWSWIRE
Latest Research Evaluating VASCEPA/VAZKEPA Trial to be Presented
26 Oct 2023 //
GLOBENEWSWIRE
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA
09 Aug 2023 //
GLOBENEWSWIRE
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA
08 Aug 2023 //
GLOBENEWSWIRE
Scottish Medicines Consortium Accepts VAZKEPAto Help Reduce Cardiovascular Risk
07 Aug 2023 //
GLOBENEWSWIRE
Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC
26 Jul 2023 //
GLOBENEWSWIRE
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA
25 Jul 2023 //
GLOBENEWSWIRE
Amarin Implements Organizational Restructuring to Strengthen the Company
18 Jul 2023 //
GLOBENEWSWIRE
Amarin Announces Vascepaa Approved to Reduce Cardiovascular Risk
21 Jun 2023 //
GLOBENEWSWIRE
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa
01 Jun 2023 //
GLOBENEWSWIRE
Amarin Highlights Data Providing Insight into Vascepa/Vazkepa (Icosapent Ethyl)
12 May 2023 //
GLOBENEWSWIRE
Amarin Announces VAZKEPA Approved by Israel`s Ministry of Health
05 Apr 2023 //
PRESS RELEASE
Amarin Announces VAZKEPA Approved by Israel`s Ministry of Health
04 Apr 2023 //
GLOBENEWSWIRE
Amarin Announces REDUCE-IT Data at ACC.23 Showing Benefit of VASCEPA/VAZKEPA
05 Mar 2023 //
GLOBENEWSWIRE
Amarin and CSL Announce Agreement to Commercialize VAZKEPA
28 Feb 2023 //
GLOBENEWSWIRE
Hikma accuses Amarin of suppressing generic versions of heart pill
22 Feb 2023 //
REUTERS
Amarin Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand
27 Jan 2023 //
GLOBENEWSWIRE
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Approval in Switzerland
07 Dec 2022 //
GLOBENEWSWIRE
Amarin Announces VAZKEPA Approved by the TGA in Australia
15 Nov 2022 //
GLOBENEWSWIRE
Amarin Highlights Key Data Presented at SAH 2022 for VASCEPA®/VAZKEPA
07 Nov 2022 //
GLOBENEWSWIRE
Amarin Makes Moves towards Global Expansion of Vazkepa
22 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Data Show VASCEPA/VAZKEPA Reduced Cardiovascular Events in Patients
28 Aug 2022 //
GLOBENEWSWIRE
Latest Research Evaluating VASCEPA and REDUCE-IT Landmark Outcomes Trial
15 Aug 2022 //
GLOBENEWSWIRE
Dr. Reddy`s Generic Icosapent Ethyl Receives Tentative Approval in the U.S.
18 Jul 2022 //
FDA
NICE Issues Guidance for Reimbursement Making VAZKEPA Available Across the NHS
13 Jul 2022 //
GLOBENEWSWIRE
Amarin Releases Post Hoc Data from REDUCE-IT Sub-Study of Vascepa
02 Jul 2022 //
TRIALSITENEWS
Exploratory Post Hoc Biomarker Sub-Analysis b/w Icosapent Ethyl & Placebo
30 Jun 2022 //
GLOBENEWSWIRE
NICE backs lipid-lowering fish oil drug for use alongside statins
14 Jun 2022 //
GPONLINE
Research Presented at AHA`s QCOR Scientific Sessions for Potential of VASCEPA
16 May 2022 //
GLOBENEWSWIRE
New Analysis Reveals Icosapent Ethyl Reduces Risk of Cardiovascular Events
03 May 2022 //
GLOBENEWSWIRE
Amarin Partner HLS Completes Reimbursement (pCPA) for VASCEPA® (icosapent ethyl)
26 Apr 2022 //
GLOBENEWSWIRE
EPA Combined with Widely Used Statins Significantly Reduced Lipid Oxidation
01 Apr 2022 //
GLOBENEWSWIRE
Latest Research Evaluating VASCEPA to be Presented at ACC
21 Mar 2022 //
GLOBENEWSWIRE
JAMA Publication Highlights VASCEPA Cardiovascular Risk Reduction
24 Feb 2022 //
GLOBENEWSWIRE
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®
15 Nov 2021 //
GLOBENEWSWIRE
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA Growth in U.S
22 Sep 2021 //
GLOBENEWSWIRE
Amarin Reports Latest Clinical Research in VASCEPA/VAZKEPA and EPA
31 Aug 2021 //
GLOBENEWSWIRE
Amarin Reports Data from REDUCE-IT trial; Significantly Reduces Ischemic Events
23 Aug 2021 //
GLOBENEWSWIRE
Clinical Research Evaluating Icosapent Ethyl to be Presented at ESC Congress
16 Aug 2021 //
GLOBENEWSWIRE
Apotex`s Gneneric Icosapent Ethyl Receives Approval In US
30 Jun 2021 //
FDA
Dr. Reddy`s Laboratories Announces the Launch of Icosapent Ethyl Capsules
22 Jun 2021 //
BUSINESSWIRE
Dr. Reddy`s Labs launches icosapent ethyl capsules in US market
22 Jun 2021 //
PHARMABIZ
Supreme Court denies Amarin`s bid to revive Vascepa drug patents
22 Jun 2021 //
REUTERS
Results of VASCEPA to Be Presented at American College of Cardiology’s Session
04 May 2021 //
PRESS RELEASE
MHRA gives green light to new cardiovascular treatment
23 Apr 2021 //
PHARMAFILE
MHRA authorises Amarin’s heart drug Vazkepa
23 Apr 2021 //
PHARMATIMES
MHRA gives green light to new cardiovascular treatment
22 Apr 2021 //
PHARMAFILE
VASCEPA (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features
19 Apr 2021 //
GLOBENEWSWIRE
